Lam Research's Buyback Machine Humming, But China Risk Looms

What happened

The news highlights Lam Research's $4.3B in remaining buyback authorization, supported by strong cash flows from AI-led demand. However, the DeepValue report reveals a more nuanced picture: robust operating performance (March quarter revenue $5.84B, gross margin 49.8%) is offset by 34% China revenue concentration and management's warning that export licenses could materially and adversely affect sales. The company spent $1.16B on buybacks in the recent quarter, yet cash on hand dropped from $6.2B to $4.77B. With the stock trading at 48.3x P/E and no margin of safety, the aggressive capital return policy increases leverage to any earnings disruption. The narrative of AI-driven strength is real, but it coexists with a bifurcated cycle and policy risk that the market may be underappreciating.

Implication

For investors, Lam's strong cash flow and buyback activity underscore healthy near-term operations, but the $4.3B remaining authorization is not a reason to buy at current prices. The DeepValue analysis shows a WAIT rating with asymmetric downside from export controls—China represents over a third of revenue, and management's language on licensing is the most bearish in recent filings. The stock's 48x P/E leaves no room for error; any guidance miss or China policy tightening could trigger a sharp revaluation. Aggressive share repurchases have reduced cash, making the balance sheet less resilient to a downturn. Position sizing should be conservative, and investors should look for a better entry near $225 or confirmation that China revenue falls below 25% while gross margins hold above 50%.

Thesis delta

The news of strong cash flows and buyback authorization reinforces the bullish AI narrative, but does not change the core thesis that Lam Research is a high-quality cyclical with policy-driven downside. The key risk—China concentration and export license uncertainty—remains unaddressed. Our thesis shifts from 'hold for AI momentum' to 'wait for a margin of safety' as the stock's valuation and capital return posture offer insufficient compensation for the regulatory overhang.